RD162 – 10 mg

Brand:
Cayman
CAS:
915087-27-3
Storage:
-20
UN-No:
Non-Hazardous - /

RD162 is a second-generation androgen receptor (AR) antagonist. It inhibits binding of 18F-FDHT to AR in human prostate cancer cells with an IC50 value of 30.9 nM.{24601} RD162 completely suppresses VCaP cell proliferation at 1 µM and induces apoptosis of VCaP cells at 10 µM. RD162 is bioavailable and reduces LNCaP/AR tumor growth in castrated male mice at a daily oral dose of 10 mg/kg.{24601}  

 

Available on backorder

SKU: 13039 - 10 mg Category:

Description

A second-generation AR antagonist (IC50 = 0.9 nM); inhibits proliferation of prostate cancer cells in culture and in mice,


Formal name: 4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methyl-benzamide

Synonyms: 

Molecular weight: 476.4

CAS: 915087-27-3

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Endocrinology & Metabolism|Hormones & Receptors|Androgens